Medicare has long excluded coverage for drugs used primarily for weight loss, creating a significant barrier for beneficiaries struggling with obesity and related conditions. GLP-1 medications like Wegovy and Zepbound have shown remarkable results in clinical trials, but their high cost has made them out of reach for many older adults. This policy gap has prompted calls for change as obesity rates continue to rise among the Medicare population.
In December 2025, the Centers for Medicare & Medicaid Services (CMS) announced a major shift. Starting July 1, 2026, a short-term demonstration program called the Medicare GLP-1 Bridge will provide limited coverage for certain weight-loss GLP-1 drugs at a $50 monthly copay for eligible beneficiaries. This pilot serves as a bridge to the longer-term BALANCE Model planned for 2027.
This article explains the current Medicare stance on weight loss drugs, details the new 2026 Bridge program, outlines eligibility and requirements, and explores what the future may hold. The information is designed to help beneficiaries understand their options and prepare for potential coverage changes.
Medicare’s Historical Stance on Weight Loss Drugs
Federal law has historically prohibited Medicare Part D from covering medications prescribed solely for weight loss. This exclusion dates back to the program’s design, which focuses on treating illness rather than preventive or cosmetic concerns. As a result, drugs like Wegovy and Zepbound have not been covered when the primary indication is obesity or weight management.
This policy has created challenges for beneficiaries with obesity-related conditions such as sleep apnea, heart disease, or joint problems. Many have paid full retail prices or gone without treatment, despite evidence that weight loss can improve overall health and reduce other Medicare-covered complications.
The exclusion has been criticized as short-sighted, especially as obesity rates among older adults have increased and new, highly effective GLP-1 medications have emerged. Advocacy efforts and growing clinical evidence have pushed CMS to explore limited coverage options.
The Medicare GLP-1 Bridge Program Starting July 2026
The Medicare GLP-1 Bridge is a short-term demonstration program running from July 1, 2026, to December 31, 2027. It provides eligible Part D beneficiaries access to specific GLP-1 medications for weight reduction and maintenance at a flat $50 monthly copay.
Eligible drugs include Wegovy (both injection and tablet forms), Zepbound (KwikPen formulation), and Foundayo. These are covered when prescribed to reduce excess body weight and maintain weight reduction in beneficiaries who meet clinical criteria, such as BMI of 35 or higher, or BMI of 27 or higher with weight-related comorbidities.
The program operates outside the standard Part D benefit structure. Copayments do not count toward the deductible or out-of-pocket maximum, and beneficiaries must be enrolled in a Part D plan but access the drugs through a central CMS-managed process.
Eligibility Requirements for the Bridge Program
To qualify, beneficiaries must have a Part D plan and meet specific clinical criteria documented by their provider. Prior authorization is required, with the provider attesting that the drug is prescribed for weight reduction and maintenance.
Key eligibility includes BMI thresholds and the presence of weight-related conditions. The program targets those who can benefit most from weight loss to improve health outcomes and potentially reduce other Medicare costs.
Enrollment is not automatic. Providers submit requests through a central processor, and eligible beneficiaries gain access at the $50 copay level. The program is designed as a bridge to the more comprehensive BALANCE Model starting in 2027.
How the BALANCE Model Fits In
The BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is the longer-term demonstration planned for January 2027. It aims to integrate GLP-1 coverage with lifestyle interventions for Medicare and Medicaid beneficiaries.
The model will test negotiated pricing, comprehensive care coordination, and outcomes-based payments. It represents a shift toward value-based care for obesity treatment, potentially making coverage more sustainable long-term.
The Bridge program provides immediate access while BALANCE is developed, allowing CMS to gather data and refine the larger initiative based on real-world results.
Current Coverage for Diabetes and Related Conditions
Medicare continues to cover GLP-1 medications like Ozempic and Mounjaro when prescribed for type 2 diabetes management. Prior authorization and step therapy still apply, but approval is more straightforward with a diabetes diagnosis.
Coverage for cardiovascular risk reduction or kidney disease progression in diabetic patients is also available under approved indications. These uses fall under standard Part D rules without the weight-loss exclusion.
This distinction means patients with diabetes have clearer access pathways, while those seeking treatment primarily for obesity rely on the new Bridge program or out-of-pocket options.
Comparison of Medicare Coverage Scenarios
Here is a concise comparison of coverage situations in 2026.
| Scenario | Coverage Status | Typical Monthly Cost | Key Requirements |
|---|---|---|---|
| Type 2 Diabetes | Covered with PA | Varies by plan | Diagnosis + step therapy |
| Obesity/Weight Loss Only | Bridge Program (July 2026) | $50 copay | BMI criteria + PA |
| No Qualifying Diagnosis | Generally not covered | Full retail price | N/A |
The table highlights how diagnosis drives coverage options. Diabetes provides the most reliable path, while the Bridge program opens limited access for weight management.
Practical Steps for Beneficiaries
Review your Part D plan documents during open enrollment to understand current coverage and any Bridge program participation. Contact member services with specific questions about GLP-1 options.
Prepare for doctor visits by bringing recent labs, weight history, and notes on comorbidities. This helps your provider submit strong prior authorization requests or Bridge program applications.
Explore manufacturer patient assistance programs if you face high costs. While Medicare beneficiaries have limited access to savings cards, other assistance options may be available based on income.
Lifestyle Support and Comprehensive Care
Medicare covers intensive behavioral therapy and medical nutrition therapy for eligible beneficiaries. These services complement medication use and support sustainable weight management.
Participating in these programs can strengthen coverage requests and improve overall outcomes. Many beneficiaries find that combining medication with coaching leads to better long-term success.
Focus on sustainable habits like balanced nutrition, regular physical activity, and stress management. These foundations enhance the effectiveness of any medication and support health beyond weight loss.
Future Outlook for Medicare Coverage
The Bridge program and BALANCE Model represent significant steps toward broader GLP-1 coverage. Data collected during these demonstrations will inform future policy decisions and potential permanent coverage.
Advocacy efforts continue to push for expanded access, recognizing obesity as a chronic disease with major health and cost implications. Changes in administration or legislation could accelerate broader coverage.
Beneficiaries should stay informed through Medicare communications and annual plan reviews. Policies will likely evolve as more evidence emerges on long-term benefits and cost-effectiveness.
Summary
Medicare does not generally cover weight loss drugs, but the new Medicare GLP-1 Bridge program starting July 1, 2026, provides limited access to certain medications like Wegovy and Zepbound at a $50 monthly copay for eligible beneficiaries. Coverage for type 2 diabetes remains more established with prior authorization and step therapy. The Bridge serves as a temporary measure until the BALANCE Model launches in 2027, which aims for more comprehensive integration of lifestyle support and medication. Beneficiaries should review their plans, work with providers on documentation, and explore assistance programs when needed. With evolving policies, more options are becoming available, but careful planning ensures access while managing costs effectively.
FAQ
When does the Medicare GLP-1 Bridge program start?
The Medicare GLP-1 Bridge program begins July 1, 2026, and runs through December 31, 2027. It provides eligible Part D beneficiaries access to select weight-loss GLP-1 drugs at a $50 monthly copay. The program operates outside standard Part D benefits.
What drugs are covered under the Medicare GLP-1 Bridge?
The program covers Wegovy (injection and tablets), Zepbound (KwikPen formulation), and Foundayo for weight reduction and maintenance. Eligibility requires specific BMI criteria and provider attestation of medical need.
Does Medicare cover GLP-1s for diabetes?
Yes, Medicare Part D covers GLP-1 medications for type 2 diabetes management with prior authorization. Coverage is more established for diabetes than for weight loss alone, though step therapy and documentation are still required.
How much will GLP-1 drugs cost under the Bridge program?
Eligible beneficiaries pay a flat $50 monthly copay. This copay does not count toward the Part D deductible or out-of-pocket maximum. Costs remain consistent regardless of the benefit phase.
What is the BALANCE Model and when does it start?
The BALANCE Model is a longer-term demonstration integrating GLP-1 coverage with lifestyle interventions. It is planned to begin in January 2027 for Medicare and Medicaid beneficiaries. The Bridge program serves as a short-term bridge to this larger initiative.
Dr. Hamza is a medical content reviewer with over 12+ years of experience in healthcare research and patient education. He specializes in evidence-based health information, medications, and chronic conditions. His reviews are grounded in trusted medical sources and current clinical guidelines to ensure accuracy, transparency, and reliability. Content reviewed by Dr. Hamza is intended for educational purposes and is not a substitute for professional medical advice.